348 related articles for article (PubMed ID: 7649075)
1. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Breeman WA; Lamberts SW
Endocrinology; 1995 Sep; 136(9):3698-706. PubMed ID: 7649075
[TBL] [Abstract][Full Text] [Related]
2. Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery.
Hofland LJ; Breeman WA; Krenning EP; de Jong M; Waaijers M; van Koetsveld PM; Mäcke HR; Lamberts SW
Proc Assoc Am Physicians; 1999; 111(1):63-9. PubMed ID: 9893158
[TBL] [Abstract][Full Text] [Related]
3. Tissue distribution and metabolism of radioiodinated DTPA0, D-Tyr1 and Tyr3 derivatives of octreotide in rats.
Breeman WA; de Jong M; Bernard B; Hofland LJ; Srinivasan A; van der Pluijm M; Bakker WH; Visser TJ; Krenning EP
Anticancer Res; 1998; 18(1A):83-9. PubMed ID: 9568060
[TBL] [Abstract][Full Text] [Related]
4. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells.
Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Lamberts SW
Endocrinology; 1994 Jan; 134(1):301-6. PubMed ID: 7903931
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
[TBL] [Abstract][Full Text] [Related]
6. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204-090).
Faglia G; Bazzoni N; Spada A; Arosio M; Ambrosi B; Spinelli F; Sara R; Bonino C; Lunghi F
J Clin Endocrinol Metab; 1991 Oct; 73(4):850-6. PubMed ID: 1653785
[TBL] [Abstract][Full Text] [Related]
7. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
8. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
[TBL] [Abstract][Full Text] [Related]
9. Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells.
Hofland LJ; van Koetsveld PM; Wouters N; Waaijers M; Reubi JC; Lamberts SW
Endocrinology; 1992 Aug; 131(2):571-7. PubMed ID: 1322274
[TBL] [Abstract][Full Text] [Related]
10. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.
de Jong M; Breeman WA; Bakker WH; Kooij PP; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt MA; Erion JL; Bugaj JE; Mäcke HR; Krenning EP
Cancer Res; 1998 Feb; 58(3):437-41. PubMed ID: 9458086
[TBL] [Abstract][Full Text] [Related]
11. Long-term in-vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels.
Hofland LJ; Velkeniers B; vd Lely AJ; van Koetsveld PM; Kazemzadeh M; Waaijers M; Hooghe-Peters EL; Lamberts SW
Clin Endocrinol (Oxf); 1992 Sep; 37(3):240-8. PubMed ID: 1424206
[TBL] [Abstract][Full Text] [Related]
12. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
[TBL] [Abstract][Full Text] [Related]
13. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
Hofland LJ; De Herder WW; Visser-Wisselaar HA; Van Uffelen C; Waaijers M; Zuyderwijk J; Uitterlinden P; Kros MJ; Van Koetsveld PM; Lamberts SW
J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
[TBL] [Abstract][Full Text] [Related]
14. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
[TBL] [Abstract][Full Text] [Related]
15. Some changes of receptor and postreceptor signal transduction regulated by somatostatin in pituitary hGH-secreting adenomas.
Deng J; Shi Y; Yin J
Chin Med J (Engl); 1997 Sep; 110(9):678-81. PubMed ID: 9642323
[TBL] [Abstract][Full Text] [Related]
16. Direct inhibitory effects of a somatostatin analog, SMS 201-995, on AR4-2J cell proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein-independent mechanism.
Viguerie N; Tahiri-Jouti N; Ayral AM; Cambillau C; Scemama JL; Bastié MJ; Knuhtsen S; Estève JP; Pradayrol L; Susini C
Endocrinology; 1989 Feb; 124(2):1017-25. PubMed ID: 2563240
[TBL] [Abstract][Full Text] [Related]
17. Structure and function of somatostatin receptors in growth hormone control.
Shimon I; Melmed S
J Endocrinol; 1997 Oct; 155 Suppl 1():S3-6; discussion S7-8. PubMed ID: 9389989
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
[TBL] [Abstract][Full Text] [Related]
19. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
Bakker WH; Albert R; Bruns C; Breeman WA; Hofland LJ; Marbach P; Pless J; Pralet D; Stolz B; Koper JW
Life Sci; 1991; 49(22):1583-91. PubMed ID: 1658515
[TBL] [Abstract][Full Text] [Related]
20. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status.
Reubi JC; Landolt AM
J Clin Endocrinol Metab; 1989 Apr; 68(4):844-50. PubMed ID: 2537844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
